Business Wire

The Nishi-Shinjuku Illumination Market Lighting Ceremony, a New Illumination in Tokyo, Held to Illuminate the Nighttime in Nishi-Shinjuku!

Share

The “TOKYO NIGHTTIME PROJECT” has been launched in the Nishi-Shinjuku area of Shinjuku-ku, Tokyo, with the aim of revitalizing night tourism. The project, by collaborating with organizations in the surrounding area, enlivens nighttime in Nishi-Shinjuku, an area where tradition and innovation intersect, with light displays and other activities to create a lively atmosphere for visitors.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241203634601/en/

The Illuminations (Photo: Business Wire)

"Nishi-Shinjuku Illumination Market” started on November 28, 2024. On Chuo-dori Avenue along the Tokyo Metropolitan Government Building, approximately 200,000 champagne gold LED lights illuminate the street for as long as 200 meters, creating a fantastic night scene, a new illumination spot in Tokyo.

At the lighting ceremony, Judoka Hifumi Abe and Uta Abe, both from the Park24 club, appeared as guests. They pressed the light button following the countdown, and the street was enveloped in glittering champagne gold lights.

TOKYO NIGHTTIME PROJECT Overview

  • Sponsor: Tokyo Nighttime Project Executive Committee
  • Co-sponsor: Tokyo Metropolitan Government
  • Programs:
    Nishi-Shinjuku Illumination Market
    New Year's Eve countdown event "Happy New Year Tokyo 2025"
  • Dates: Thursday, November 28th, 2024 to Monday/National holiday, January 13th, 2025
  • TOKYO NIGHTTIME PROJECT official website
    https://tokyo-nighttime-project.jp/en/
  • Nishi-Shinjuku Illumination Market Overview
    In addition to the illumination, food trucks and markets will line up, selling foods and goods that give a sense of Edo culture. For details, please visit the event website https://tokyo-nighttime-project.jp/en/market/
  • New Year’s Eve Countdown event “Happy New Year Tokyo 2025” Overview
    "Happy New Year Tokyo 2025” will be held on New Year's Eve to close the year, a countdown event for many people including the Tokyo residents and foreign visitors, to experience the charms of Tokyo and share the anticipation for the New Year together.
    With the theme of tradition and innovation, which are the attractions of Tokyo, there will be projection mapping, live performances by Japanese drummers and DJs, and talk shows by guests. In addition, new year wishes by the participants will be projected in the form of digital ema (votive picture tablet).
    For details, please visit the event website https://tokyo-nighttime-project.jp/en/countdown/

The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the source-language text, which is the only version of the text intended to have legal effect.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241203634601/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release

Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem

Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 11:08:00 CET | Press release

Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played

Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 10:44:00 CET | Press release

At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will

Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 10:00:00 CET | Press release

Anthropic’s safety-first AI meets Allianz's dedication to customer centricity, stakeholder trust, and regulatory excellenceThree focus areas of the partnership: workforce empowerment, operations automation through agentic AI, and regulatory compliance Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE.

MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 07:00:00 CET | Press release

MH002 is currently the most advanced Live Biotherapeutic Product (LBP) based on a rationally-designed combination of disease specific bacteria (microbial consortia), for the treatment of inflammatory bowel diseases (IBD) STARFISH-UC Phase 2b trial is designed to confirm MH002’s early efficacy signals and favorable safety observed in Phase 2a studies MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye